Comparative Pharmacology
Head-to-head clinical analysis: OVULEN 21 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVULEN 21 versus TRI SPRINTEC.
OVULEN-21 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; inhibits gonadotropin release, suppressing ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet (ethinyl estradiol 0.05 mg and norethindrone 1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norethindrone: 5-14 hours (mean ~8 hours); terminal half-life supports once-daily dosing.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: 50-60% as metabolites; fecal: 30-40% as conjugates; biliary excretion significant.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive